Electronic Case Report Form

PROTOCOL	2021년 7월 교육실습			
STUDY TITLE	2021년 7월 교육실습 (이송영)			

SITE	_
책임 연구자	_
CRF Version	1.00
CRF Effective	-
스크리닝 번호	_
배정 번호	-
이니셜	-

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습		

	Enrollme nt	V1	V2	V3	V4	V5	UV1	All
Enrollme nt								
Visit								
Demogra phics								
Medical History								
Vital Signs								
Local Laborato ry Test								
Pregnanc y Test								
Inclusion/ Exclusion Criteria								
Randomi zation								
IP Prescripti on								
Adverse Event								
Prior and Concomi tant Medicati ons								
Dispositi on								
Principal Investigat or's Signature								

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Enrollment	Enrollment

Enrollment				
Date of informed consent	EN.ICDTC (C10)			
Screening No.	EN.SUBJID (C6)			

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Visit	V1, V2, V3, V4, V5, UV##

Visit	
Visit date	
Reason for unscheduled visit	SV.SVUVREAS (N2) [1] ○ Adverse event [2] ○ Others → Specify below
Others, specify	SV.SVUVRECO (C10)

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Visit	V1, V2, V3, V4, V5, UV##

Level	ID	Property	Visit	Type	Cycle No.	Value
QST	SVUVR EAS		All	Exclude	All	Reason for unscheduled visit
QST	SVUVR EAS		UV##	Include	All	Reason for unscheduled visit
QST	SVUVR ECO		All	Exclude	All	Others, specify
QST	SVUVR ECO		UV##	Include	All	Others, specify

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Demographics	V1

Demographics	
Birth date	DM.BRTHDTC (C10)
Age	DM.AGE (N2) 만 _ Years
Sex	DM.SEX (N2) [1] Male [2] Female
Alcohol	DM.ALCOHOL (N2) [1] O Yes [2] O No

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Medical History	V1

Medical History					
ND MY.MHND (N1) [1] □ ND					
No	Medical history term		Ongoing	End date	Administration of medication
MH.SEQ (N2) 1	MH.MHTERM (C255)		MH.MHONGO (N2) [1] O Yes [2] O No	MH.MHENDTC (C10)	MH.MHCONTRT (N2) [1] O Yes [2] O No

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Vital Signs	V1, V2, V3, V4, V5, UV##

Vital Signs			
ND	VS.VSND (N1)		
Height	CM		
Weight	VS.WEIGHT (N3.1)		
Systolic blood pressure	mmHg		
Diastolic blood pressure	mmHg		
Pulse rate	beats/min		
Respiratory rate	breaths/min		
Temperature	℃		
If there are any newly noted clinically significant abnormal result since the last Visit, please specify the details on the [Adverse Event] page			

CRF V1.00[-] Confidential 8 / 21

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Vital Signs	V1, V2, V3, V4, V5, UV##

Level	ID	Property	Visit	Type	Cycle No.	Value
QST	HEIGH T		All	Exclude	All	Height
QST	HEIGH T		V1	Include	All	Height

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Local Laboratory Test	V1, V2, UV##

Local Laboratory Test				
ND	LY,LBND (N1) [1] ND			
Collection date	LY.LBDTC (C10)			
*If there are any newly noted abnormal result since the last Visit, please specify the details on the [Adverse Event] page				

Hematology			
Test Name	Result	Normality	Clinically Significant
LB.LBTEST (C50) Erythrocytes	LB.LBORRES (N4.3)	LB.LBNOR (N2) [1] ○ Normal [2] ○ Abnormal	LB.LBCLSIG (N2) [1] O NCS [2] O CS
LB.LBTEST (C50) Hemoglobin	LB.LBORRES (N4.3)	LB.LBNOR (N2) [1] O Normal [2] O Abnormal	LB.LBCLSIG (N2) [1] O NCS [2] O CS
LB.LBTEST (C50) Hematocrit	LB.LBORRES (N4.3)	LB.LBNOR (N2) [1] O Normal [2] O Abnormal	LB,LBCLSIG (N2) [1] O NCS [2] O CS
LB.LBTEST (C50) Platelets	LB.LBORRES (N4.3)	LB.LBNOR (N2) [1] O Normal [2] O Abnormal	LB,LBCLSIG (N2) [1] O NCS [2] O CS
LB.LBTEST (C50) Leukocytes	LB.LBORRES (N4.3)	LB.LBNOR (N2) [1] O Normal [2] O Abnormal	LB.LBCLSIG (N2) [1] O NCS [2] O CS

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Local Laboratory Test	V1, V2, UV##

Level	ID	Property	Visit	Type	Cycle No.	Value
QST	LBND		All	Include	All	ND
QST	LBDTC	COMMENT_ APPEND	V1	Include	All	*If there are any clinically significant abnormal result, please specify the details on the [Adverse Event] page.

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Pregnancy Test	V1, V2, V3

Pregnancy Test			
Was the pregnancy test performed?	PG.PGYN (N2) [1] O Yes [2] O No		
Collection date	PG.PGDTC (C10)		
Result	PG.PGORRES (N2) [1] O Positive [2] O Negative		

PROTOCOL	PAGE	VISIT	
2021년 7월 교육실습	Inclusion/Exclusion Criteria	V1	

Inclusion/Exclusion Criteria			
Is the Subject eligible to participate in this clinical trial due to having satisfied all eligibility criteria?	IE,IEYN (N2) [1] ○ Yes [2] ○ No		
Date of screening failure			
Reason of screening failure	IE.IEREAS (N2) [1] ○ Inclusion/Exclusion criteria not met → Specify below [2] ○ Subject's consent withdrawal [3] ○ Other → Specify below		
Specify the reason of screening failure	IE.IEREASCO (C255)		

Inclusion Criteria

- 1. Subject who is outpatient, either male or female, aged between 19 and 74 years old, inclusive.
- 2. Subject who has a Hemoglobin A1c (HbA1c) value between 7.0% and 9.0% at Visit 1.
- 3. Subject who has estimated glomerular filtration rate (eGFR) \geq 45mL/min/1.73m^2.
- 4. Subject who has systolic blood pressure value at Visit 1.
- a) Treated with antihypertensive drugs: systolic blood pressure < 180 mmHg
- b) non-treated: 140mmHg ≤ systolic blood pressure < 180mmHg

Exclusion Criteria

- 1. Subject who has been diagnosed with type 1 diabetes mellitus.
- 2. Subject has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value exceeding 3 times of upper limit of the normal range, or bilirubin value exceeding 3 times of upper limit of the normal range at Visit 1.
- 3. Female subject of childbearing potential, who is not at least one year post-menopausalor is not surgically sterile, has positive for the pregnancy test (urine or serum) at Visit 1 or is not willing to use appropriate contraception during the study. Female subject is hoping to become pregnant or is currently pregnant or breast-feeding.

PROTOCOL	PAGE	VISIT	
2021년 7월 교육실습 Inclusion/Exclusion Criteria		V1	

- 4. Subject who has a history of clinically significant acute artery disease(s) within 3 months prior to date of Visit 1.
- 5. Subject who has a history of heart failure or arrhythmia within 6 months prior to date of Visit 1.
- 6. Subject with secondary dyslipidemia or iatrogenic dyslipidemia at Visit 1.
- 7. Subject who has a history of malignant tumor

PROTOCOL	PAGE	VISIT	
2021년 7월 교육실습	Randomization	V2	

Randomization			
Is patient randomized?	RN.RNYN (N2) [1] O Yes [2] O No		
Strata	RN.RNSRATA (N2) [1] ○ 1 [2] ○ 2		
Randomization No.			

PROTOCOL PAGE		VISIT	
2021년 7월 교육실습 IP Prescription		V1, V2, V3, V4, V5	

IP Prescription			
Is the IP prescribed?	IP.IPYN (N2) [1] ○ Yes [2] ○ No		
Date of prescription [Click SAVE the bottom of the page to allocate IP]			
IP_CODE [Click SAVE the bottom of the page to allocate IP]			

PROTOCOL PAGE		VISIT	
2021년 7월 교육실습 Adverse Event		Adverse Event	

Adverse Event					
ND [1] □ ND			AY.AEND (N1)		
Rec	ord all adverse e	vents noted from Vis	it 1 to study completio	n.	
Li		Start date	Start date Outcome End date SAE		
n e N u m b er	Adverse Event	Severity	Relationship to study treatment	Action taken with study treatement	Other action taken
A E. S E Q (N 2)	AE.AETERM (C255)	AE.AESTDTC (C10)	AE.AEOUT (N2)▼	AE,AEENDTC (C10)	AE.AESER (N2)▼
		AE.AESEV (N2) ▼	AE.AEREL (N2)	AE.AEACN (N2)▼	AE.AEACNOTH (N2)
AE.AEOUT (N2) Outcome				red , [3] Recovered/Resol n sequelae , [5] Recoverin	
AE.AESER (N2)		[1] No , [2] Death , [3] Hospitalization , [4] Life threatening , [5] Congenital anomaly or birth defect , [6] Significant disability , [7] Other medically important event			
AE.AESEV (N2) Severity		[1] Mild , [2] Moderate , [3] Severe			
AE.AEREL (N2) Relationship to study treatment		[1] Not related , [2] Unlikely related , [3] Possibly related , [4] Related			
AE.AEACN (N2) Action taken with study treatement		[1] Dose increased , [2] Dose not changed , [3] Dose reduced , [4] Drug interrupted , [5] Drug withdrawn , [6] Not applicable , [7] Unknown			
AE.AEACNOTH (N2) Other action taken			[1] None , [2] Drug treatment , [3] Non-drug treatment , [4] Drug and non-drug treatment		

PROTOCOL	PAGE	VISIT	
Prior and Concomitant Medications		Prior and Concomitant Medications	

Prior and Concomitant Medications					
ND	[1] □ ND	CY.CMND (N1)			
Please record all me	dications within 4 we	eks prior to Visit 1 exc	ept for IP.		
Line Number	Medication or therapy	Total daily dose	Dose Unit	Route	
	Start date	Ongoing	End date	Indication	
	CM.CMTRT (C255)	CM.CMDOSTOT (N5.3)	CM.CMDOSU (C255)	CM.CMROUTE (C255)	
CM.SEQ (N2)	CM.CMSTDTC (C10)	CM.CMONGO (N1)	CM.CMENDTC (C10)	CM.CMINDC (N1) CM.CMINDCMH (C255) CM.CMINDCAE (C255) CM.CMINDCO (C255)	
CM.CMINDC (N1) Indication		[1] Medical history , [2] Adverse event , [3] Other			
СМ.СМІNDСМН (C255) Medical history					
CM.CMINDCAE (C255) Adverse event					

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Prior and Concomitant Medications	Prior and Concomitant Medications

	CM.CMINDCO (C255)
Other	CIVI, CIVIII VID CO (CZ33)

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Disposition	Disposition

Disposition		
What was the subject's status?	DS.DSDECOD (N2) [1] ○ Completed [2] ○ Withdrawal	
What was the date of study completed/withdrawal?	DS.DSDTC (C10)	
Reason for withdrawal	DS.DSREAS (N2) [1] ○ Failure to meet randomization criteria → Specify below [2] ○ Withdrawal by subject [3] ○ Lost to follow-up [4] ○ Adverse event [5] ○ Others → Specify below	
Comment	DS.DSREASO (C255)	

PROTOCOL	PAGE	VISIT
2021년 7월 교육실습	Principal Investigator's Signature	Principal Investigator's Signature

Principal Investigator's Signature	
Investigator's Signature	SN.SNNAME (C10)
Signature Date	SN.SNDTC (C30)